Mercaptopurine (6-MP)

Catalog No.S1305

For research use only.

Mercaptopurine is a widely used antileukemic agent and immunosuppressive drug that inhibits de novo purine synthesis through incorporation of thiopurine methyltransferase metabolites into DNA and RNA.

Mercaptopurine (6-MP) Chemical Structure

CAS No. 50-44-2

Selleck's Mercaptopurine (6-MP) has been cited by 10 Publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Other DNA/RNA Synthesis Products

Biological Activity

Description Mercaptopurine is a widely used antileukemic agent and immunosuppressive drug that inhibits de novo purine synthesis through incorporation of thiopurine methyltransferase metabolites into DNA and RNA.
Targets
PRPP Amidotransferase [2]
In vitro

Mercaptopurine is widely used to treat malignancies, rheumatic diseases, dermatologic conditions, inflammatory bowel disease, and solid organ transplant rejection. [1] Mercaptopurine inhibits purine nucleotide synthesis and metabolism by inhibiting an enzyme called Phosphoribosyl pyrophosphate amidotransferase (PRPP Amidotransferase). PRPP Amidotransferase is the rate limiting enzyme of purine synthesis. It alters the synthesis and function of RNA and DNA . Mercaptopurine interferes with nucleotide interconversion and glycoprotein synthesis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
L1210 leukemia cells M37VRmZ2dmO2aX;uJIF{e2G7 M1fJU2lvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDvckBufWy2aXTyeYcuemW|aYP0ZY51KExzMkGwJIxmfWunbXnhJINmdGy|LDDJR|UxRTBwMEK0JO69VQ>? MUexPVA3OTB5
MT4 cells Mn[1VJJwdGmoZYLheIlwdiCjc4PhfS=> M37nVWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTWS0JINmdGy|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlEh|ryP MmrJNVczPTR4Nkm=
human CCRF-CEM cells MXLQdo9tcW[ncnH0bY9vKGG|c3H5 NHHPdGlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPDVmYuS0WPIHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1zIN88US=> NVnzR2lyOTd{NUS2Olk>
human CCRF-SB cells M3K3[HBzd2yrZnXyZZRqd25iYYPzZZk> MoPzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFQ2LGMXNDKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0yKM7:TR?= NXzPbW8yOTd{NUS2Olk>
human SK-MEL-28 cells NG\GNnZRem:uaX\ldoF1cW:wIHHzd4F6 M2HSfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUWVNNTJ6IHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1zNTFOwG0> NYnCUoVROTd{NUS2Olk>
human MCF7 cells NVrMdZBPWHKxbHnm[ZJifGmxbjDhd5NigQ>? M1zvTWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDifUBOXFRiYYPzZZktKEmFNUC9N{DPxE1? MYKxO|I2PDZ4OR?=
human HepG2 cells MXrQdo9tcW[ncnH0bY9vKGG|c3H5 NYHwUo5ISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:QCEQvF2= NUjpVXpYOTd{NUS2Olk>
human DU145 cells NHTSWWJRem:uaX\ldoF1cW:wIHHzd4F6 MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JINmdGy|IHL5JG1VXCCjc4PhfUwhUUN3ME2yJO69VQ>? MXuxO|I2PDZ4OR?=
mouse J774.A1 cells NHLFOXdRem:uaX\ldoF1cW:wIHHzd4F6 NH33Wow{KGSjeYO= MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEp5N{SuRVEh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IF3UWEBkd264ZYLzbY9vKGG|c3H5MEBKSzVyPUCuNFA{KM7:TR?= NV64UFM4OTZ4NEOwOFA>
HEK293 cells M3\TT3Bzd2yrZnXyZZRqd25iYYPzZZk> MXyzJIRigXN? MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFjFT|I6OyClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGOxbo\ldpNqd25iYYPzZZktKEmFNUC9NE4xODdizszN NVHNOG8yOTZ4NEOwOFA>
mouse J774 cells NW\RZno3WHKxbHnm[ZJifGmxbjDhd5NigQ>? MmDoO|IhcA>? NEfLbpJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFq3O|Qh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIHPlcIwh\3Kxd4ToJIFnfGW{IEeyJIhzeyCkeTDNWHQhdWW2aH;kMEBKSzVyPUCuNFA{KM7:TR?= MoTmNVA4PTd5MEi=
human PBMC MmH1SpVv[3Srb36gZZN{[Xl? MWG0JIRigXN? NVrLc|J7UW6qaXLpeIlwdiCxZjDUJINmdGxibXn0c4dmdi2rbnT1Z4VlKGKuYYP0c4dmdmW|aYOgbY4hcHWvYX6gVGJOSyCjZoTldkA1KGSjeYOsJGlEPTB;MD6xOFk2KM7:TR?= NH:xXnEyQDR4N{CwOy=>
HeLa cells NXexcHN5S3m2b4TvfIlkcXS7IHHzd4F6 NUCzZ4JyPDhiaB?= MofXR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{BifCCuYXegdIhie2Vib3[g[5Jwf3SqIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:Oi57IN88US=> NVv5N4NuOTl5MUG5PFc>
A549 cells Mo[3R5l1d3SxeHnjbZR6KGG|c3H5 MYC0PEBp M{S4UGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[XRibHHnJJBp[XOnIH;mJIdzd3e2aDDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTR5IN88US=> MnjZNVk4OTF7OEe=
MCF7 cells NF\TVmhEgXSxdH;4bYNqfHliYYPzZZk> Ml7LOFghcA>? MWfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF1KGyjZzDwbIF{\SCxZjDndo94fGhiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yNjRizszN NYLKfZVHOTl5MUG5PFc>
MT4 cells M2nSeWN6fG:2b4jpZ4l1gSCjc4PhfS=> NXi1RYFjQTZiaB?= MmTyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXQ1KGOnbHzzJIlv\mWldHXkJJdqfGhiSGTMWk0yKGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEOFNUC9NE4yKM7:TR?= M4HYdlIyPzRzMUOw
CCRF-CEM cells Mn3tVJJwdGmoZYLheIlwdiCjc4PhfS=> M{O4blk3KGh? NFuzVpZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPDVmYuS0WPIHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEOFNUC9NUDPxE1? Mo\pNlE4PDFzM{C=
WIL2-NS cells NXfkOXJ6WHKxbHnm[ZJifGmxbjDhd5NigQ>? Mm\kPVYhcA>? NY\mUIV1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDXTWwzNU6VIHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEOFNUC9N{DPxE1? NGm1RWgzOTd2MUGzNC=>
CCRF-SB cells M1TLSnBzd2yrZnXyZZRqd25iYYPzZZk> MYC5OkBp M33pU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ1PSSk1USiClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBESzVyPUGuNUDPxE1? NHf6OlMzOTd2MUGzNC=>
human DU145 cells MUTQdo9tcW[ncnH0bY9vKGG|c3H5 NVPoSnJiQTZiaB?= MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JINmdGy|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFPDOVA:OiEQvF2= MWeyNVc1OTF|MB?=
human HepG2 cells NEfJZXFRem:uaX\ldoF1cW:wIHHzd4F6 M{\HdVk3KGh? MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFPDOVA:QCEQvF2= M2LRWFIyPzRzMUOw
MCF7 cells MYrQdo9tcW[ncnH0bY9vKGG|c3H5 MnewPVYhcA>? NFvJeoFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IF3UWEBie3OjeTygR2M2OD1|LkKg{txO MWKyNVc1OTF|MB?=
SK-MEL-28 cells NHK4SHhRem:uaX\ldoF1cW:wIHHzd4F6 MUm5OkBp MmPNRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVSz3NSWwuOjhiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JG1VXCCjc4PhfUwhS0N3ME2xOUDPxE1? M4T6TVIyPzRzMUOw
MCF7 cells NXjJT|BFS3m2b4TvfIlkcXS7IHHzd4F6 MmqwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{whUUN3ME2yMlc6KM7:TR?= MWiyN|QyOTlzNR?=
mouse S49 cells M1;qWGN6fG:2b4jpZ4l1gSCjc4PhfS=> NX7PSpU2PzJiaB?= MkDjR5l1d3SxeHnjbZR6KGGpYXnud5Qhf2muZDD0fZBmKG2xdYPlJHM1QSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhfHK7cHHuJIJtfWViZYjjcJV{cW:wIHHzd4F6NCCHQ{WwQVgh|ryP NH62XoEzOjF4NUi=
Colo-357 cells MV3DfZRwfG:6aXPpeJkh[XO|YYm= MnH2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR49tdy1|NUegZ4VtdHNiYomgZ5J6e3SjbDD2bY9t\XRic4ThbY5qdmduIFnDOVA:Pi5zMjFOwG0> M{DuTlIxQTNyMUKz
Aspc-1 cells MXLDfZRwfG:6aXPpeJkh[XO|YYm= MUnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBd5BkNTFiY3XscJMh[nliY4L5d5RidCC4aX;s[ZQhe3SjaX7pcoctKEmFNUC9Nk41PSEQvF2= M1P4V|IxQTNyMUKz
A549 cells NIDmeplEgXSxdH;4bYNqfHliYYPzZZk> NV\VXJIzPDhiaB?= M3fM[WN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20O{DPxE1? MXuyNlcxPTByMR?=
MCF7 cells MWLDfZRwfG:6aXPpeJkh[XO|YYm= M4L3VVQ5KGh? MmX5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGuOEDPxE1? NHjwPXQzOjdyNUCwNS=>
Patu-02 cells NH3UWXREgXSxdH;4bYNqfHliYYPzZZk> M4\EdGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBifHVvMEKgZ4VtdHNiYomgZ5J6e3SjbDD2bY9t\XRic4ThbY5qdmduIFnDOVA:QS54OTFOwG0> M{jZXVIxQTNyMUKz
Patu-T cells NGTueY1EgXSxdH;4bYNqfHliYYPzZZk> NY\uNYp1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWGG2dT3UJINmdGy|IHL5JINzgXO2YXygeolwdGW2IIP0ZYlvcW6pLDDJR|UxRTRwMEmg{txO M2P5VFIxQTNyMUKz
Patu-S cells NETzNZdEgXSxdH;4bYNqfHliYYPzZZk> M{DuUWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBifHVvUzDj[YxteyCkeTDjdpl{fGGuII\pc4xmfCC|dHHpcolv\yxiSVO1NF0yOS5yNzFOwG0> NX7SUodGOjB7M{CxNlM>
T3M4 cells NVPUTYE1S3m2b4TvfIlkcXS7IHHzd4F6 MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDUN201KGOnbHzzJIJ6KGO{eYP0ZYwhfmmxbHX0JJN1[WmwaX7nMEBKSzVyPUKuOlMh|ryP M1;xZVIxQTNyMUKz
human PANC1 cells Mn\KR5l1d3SxeHnjbZR6KGG|c3H5 MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQRW5EOSClZXzsd{BjgSClconzeIFtKH[rb3zleEB{fGGrbnnu[{whUUN3ME22MlM6KM7:TR?= NIji[G0zODl|MEGyNy=>
human DAN-G cells M3PORWN6fG:2b4jpZ4l1gSCjc4PhfS=> NXjwW2ptS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTEGQLVegZ4VtdHNiYomgZ5J6e3SjbDD2bY9t\XRic4ThbY5qdmduIFnDOVA:PC5yNjFOwG0> NV36V|JVOjB7M{CxNlM>
HeLa cells NXvreVVpS3m2b4TvfIlkcXS7IHHzd4F6 Mn2wOFghcA>? NV3uflE{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVIvQSEQvF2= NE\nfHgzOjdyNUCwNS=>
WEHI164 cells M{f2e3Bzd2yrZnXyZZRqd25iYYPzZZk> MnP5N{Bl[Xm| MlTHRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCZRVjJNVY1KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDNWHQh[2:wdnXyd4lwdiCjc4PhfUwhUUN3ME2wMlAyPSEQvF2= MUixOlY1OzB2MB?=
WIL-2NS cells NYi4PIZTWHKxbHnm[ZJifGmxbjDhd5NigQ>? NHrje|NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGfJUE0zVlNiY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTNizszN NXmzTphWOTd{NUS2Olk>
WEHI164 cells MoWwVJJwdGmoZYLheIlwdiCjc4PhfS=> NH7iSm04OiCq M4\KWGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViV1XITVE3PCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gZ4VtdCCpcn;3eIgh[W[2ZYKgO|IhcHK|IHL5JG1VXCCvZYToc4QtKEmFNUC9NE4xOTdizszN Ml;kNVA4PTd5MEi=

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 30 mg/mL
(197.13 mM)
Water Insoluble
Ethanol Insoluble

Chemical Information

Molecular Weight 152.18
Formula

C5H4N4S

CAS No. 50-44-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=NC2=C(N1)C(=S)N=CN2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04770922 Enrolling by invitation -- Acute Lymphoblastic Leukemia Pediatric|Adverse Drug Event Cipherome Inc.|Stanford University February 23 2021 --
NCT03022747 Unknown status Drug: Allopurinol|Drug: Standard treatment Lymphoblastic Leukemia Acute Childhood Vastra Gotaland Region January 2017 Phase 2
NCT04304950 Recruiting Drug: Evening Group|Drug: Morning Group Inflammatory Bowel Diseases Rush University Medical Center April 25 2016 Phase 4
NCT03920813 Unknown status Drug: Mercaptopurine Acute Lymphoblastic Leukemia Shandong University January 2015 Phase 4

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Mercaptopurine (6-MP) | Mercaptopurine (6-MP) supplier | purchase Mercaptopurine (6-MP) | Mercaptopurine (6-MP) cost | Mercaptopurine (6-MP) manufacturer | order Mercaptopurine (6-MP) | Mercaptopurine (6-MP) distributor